Both LAMA (21% vs 13%; P =0.06) and oral corticosteroid (27% vs 19%; P =0.13) use by benralizumab-eligible patients were greater than benralizumab-ineligible patients but these differences did not reach statistical significance ( Table 4 ).
← all excerpts
Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort.
1
—
—